Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex.

Pennington, Luke F; Gasser, Pascal; Kleinboelting, Silke; Zhang, Chensong; Skiniotis, Georgios; Eggel, Alexander; Jardetzky, Theodore S (2021). Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex. Nature Communications, 12(1), p. 7069. Springer Nature 10.1038/s41467-021-27397-z

[img]
Preview
Text
Directed_evolution.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (6MB) | Preview

Antibody drugs exert therapeutic effects via a range of mechanisms, including competitive inhibition, allosteric modulation, and immune effector mechanisms. Facilitated dissociation is an additional mechanism where antibody-mediated "disruption" of stable high-affinity macromolecular complexes can potentially enhance therapeutic efficacy. However, this mechanism is not well understood or utilized therapeutically. Here, we investigate and engineer the weak disruptive activity of an existing therapeutic antibody, omalizumab, which targets IgE antibodies to block the allergic response. We develop a yeast display approach to select for and engineer antibody disruptive efficiency and generate potent omalizumab variants that dissociate receptor-bound IgE. We determine a low resolution cryo-EM structure of a transient disruption intermediate containing the IgE-Fc, its partially dissociated receptor and an antibody inhibitor. Our results provide a conceptual framework for engineering disruptive inhibitors for other targets, insights into the failure in clinical trials of the previous high affinity omalizumab HAE variant and anti-IgE antibodies that safely and rapidly disarm allergic effector cells.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology and Immunology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Rheumatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Rheumatologie

UniBE Contributor:

Gasser, Pascal, Eggel, Alexander

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2041-1723

Publisher:

Springer Nature

Language:

English

Submitter:

Lee-Anne Brand

Date Deposited:

21 Dec 2021 15:05

Last Modified:

05 Dec 2022 15:57

Publisher DOI:

10.1038/s41467-021-27397-z

PubMed ID:

34862384

BORIS DOI:

10.48350/162399

URI:

https://boris.unibe.ch/id/eprint/162399

Actions (login required)

Edit item Edit item
Provide Feedback